Objectives: To examine the impact of various treatment modalities on survival among patients with bladder cancer who were 80 years old or older compared with younger patients. A compendium of evidence suggests that bladder cancer surgery is safe among octogenarians; however, the benefit of such treatment in a population with limited life expectancy has not been well documented.

Methods: Subjects with the primary diagnosis of bladder cancer were identified from the National Cancer Institute's Surveillance, Epidemiology, and End Results cancer registry between 1988 and 1999. Of the 13,796 patients diagnosed with bladder cancer, 24% were older than 80 years of age. Proportional hazards regression modeling was performed to determine the independent association of treatment strategy on overall and bladder cancer survival while adjusting for multiple covariates.

Results: Of patients 80 years old or older, bladder cancer management included watchful waiting (7%), radiotherapy alone (1%), full or partial cystectomy (12%), and transurethral resection (79%). Patients 80 years old or older were less likely to be treated with extirpative surgery than their younger counterparts (P <0.0001). Cox proportional hazards models demonstrated that, among patients 80 years old or older, radical cystectomy/partial cystectomy had the greatest risk reduction in death from bladder cancer (hazard ratio 0.3) and death from any cause (hazard ratio 0.4) among the primary treatment modalities (both P <0.0001).

Conclusions: Disparities in practice patterns between younger and geriatric patients with bladder cancer exist. We provide compelling evidence that aggressive surgical management of bladder cancer in these patients may improve survival. Risk adjustment tools should be used to identify patients (young and old) who would be better served by less aggressive management.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2004.03.034DOI Listing

Publication Analysis

Top Keywords

bladder cancer
28
years older
16
patients years
12
cancer
9
survival patients
8
bladder
7
patients
6
years
5
older
5
aggressive treatment
4

Similar Publications

: Diabetes mellitus (DM) is associated with worse surgical outcomes, and is a risk factor for bladder cancer and subsequent oncological outcomes. This study evaluated outcomes robot-assisted radical cystectomy (RARC) compared to open radical cystectomy (ORC) in patients with DM. : Data of adults ≥ 18 years old with DM who underwent radical cystectomy were extracted from the United States National Inpatient Sample database 2005-2018.

View Article and Find Full Text PDF

Bladder cancer (BC) is a prevalent urinary malignancy and muscle-invasive bladder cancer (MIBC) is particularly aggressive and associated with poor prognosis. One of MIBC features is the nuclear atypia. However, the molecular mechanism underlying MIBC remains unclear.

View Article and Find Full Text PDF

Exploration of molecular markers is an ongoing focus in the field of bladder cancer research. Based on data from public databases, was identified as upregulated in bladder urothelial carcinoma (BLCA); however, its exact function and regulatory mechanism in this context remain unclear. To investigate the clinical implications of , we examined its levels in 90 BLCA and adjoining normal tissue samples.

View Article and Find Full Text PDF

Feasible approaches for arsenic speciation analysis in foods for dietary exposure assessment: a review.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess

January 2025

Department of Food Science and Nutrition, Hong Kong Polytechnic University, Kowloon, Hong Kong, China.

Arsenic (As) occurs naturally in different forms and oxidation states. Amongst them, inorganic arsenic (iAs) is classified as both genotoxic and carcinogenic whilst other organic arsenic species are considered less toxic. As in rice is mainly present in the form of iAs which therefore poses a health risk to populations that consume rice as a staple food.

View Article and Find Full Text PDF

Introduction: Approximately 75% of bladder cancer cases are non-muscle invasive at diagnosis. Drug development for non-muscle invasive bladder cancer (NMIBC) has historically lagged behind that of other malignancies. No treatment has demonstrated the ability to overcome drug resistance that ultimately leads to recurrence and progression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!